---
title: "Croma-Pharma Announces FDA Approval of Obagi saypha® ChIQ™ in the United States"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291403581.md"
description: "In Leobendorf, Austria, Croma-Pharma celebrates a significant achievement in the first half of 2026 with the recent FDA approval of Obagi saypha® ChIQ™ in the United States. This injectable hyaluronic acid gel, developed by Croma-Pharma and brought to market by Obagi Medical, a Waldencast company, is now authorized for cheek augmentation and midface contour correction in adults aged 21 and over. This milestone marks a key development for the company in expanding its product portfolio."
datetime: "2026-07-01T10:40:12.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291403581.md)
  - [en](https://longbridge.com/en/news/291403581.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291403581.md)
---

# Croma-Pharma Announces FDA Approval of Obagi saypha® ChIQ™ in the United States

In Leobendorf, Austria, Croma-Pharma celebrates a significant achievement in the first half of 2026 with the recent FDA approval of Obagi saypha® ChIQ™ in the United States. This injectable hyaluronic acid gel, developed by Croma-Pharma and brought to market by Obagi Medical, a Waldencast company, is now authorized for cheek augmentation and midface contour correction in adults aged 21 and over. This milestone marks a key development for the company in expanding its product portfolio.

### Related Stocks

- [WALD.US](https://longbridge.com/en/quote/WALD.US.md)
- [WALDW.US](https://longbridge.com/en/quote/WALDW.US.md)

## Related News & Research

- [Regentis Biomaterials posts investor deck on GelrinC off-the-shelf knee cartilage repair hydrogel](https://longbridge.com/en/news/295661011.md)
- [18:09 ET/C O R R E C T I O N -- Green Evolution Technologies/](https://longbridge.com/en/news/295715763.md)
- [08:44 ETAlafair Biosciences Named to the 2026 Inc. 5000, Marking 4th Consecutive Year on the List](https://longbridge.com/en/news/295539003.md)
- [Marksans Pharma Limited (NSE:MARKSANS) Looks Like A Good Stock, And It's Going Ex-Dividend Soon](https://longbridge.com/en/news/296012326.md)
- [Helus Pharma cites currency switch, share consolidation and Nasdaq move as key Q1 FY2027 factors for Cybin](https://longbridge.com/en/news/295929453.md)